Pfizer’s RSV vaccine to protect babies gets greenlight from FDA

The FDA has approved Pfizer’s first RSV vaccine for expectant mothers, aimed at protecting newborn babies in their first six months of life.

Highlights: FDA approves Pfizer’s RSV vaccine for expectant mothers
* Pfizer’s new shot, named Abrysvo, will be administered during the third trimester of pregnancy to protect infants from the lower respiratory tract diseases caused by respiratory syncytial virus (RSV).
* RSV, a common virus that can lead to severe symptoms in infants, young children, and older adults, results in up to 80,000 hospitalizations of children under 5 annually, making it a leading cause of hospitalization in this age group.
* In May, an FDA committee voted unanimously in favor of the vaccine’s effectiveness, leading to its recent approval.

Effective Results: Efficacy of the New Vaccine
* A study conducted on 7,400 women in 18 countries found Pfizer’s vaccine to be 82% effective at preventing severe disease in infants during their first three months of life and 70% effective within the first six months.

Future Outlook: Anticipation for the Coming Winter
* Medical professionals are optimistic about facing the coming winter season, considering the promising options against RSV.
* Last year’s early emergence of RSV overwhelmed many children’s hospitals, highlighting its potential to strain healthcare resources.
* The vaccine, already approved for adults over 60 in May, is available for the 2023-24 RSV season, and Pfizer expects to meet the demand with enough supply.

View original article on NPR

This summary was created by an AI system. The use of this summary is subject to our Terms of Service.

Contact us about this post

Posted

in

by

Tags:

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *